P0617LEISURE-TIME PHYSICAL ACTIVITY AND MORTALITY IN CHRONIC KIDNEY DISEASE: NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES) 1999-2012. (6th June 2020)

• Record Type: Journal Article
• Authors: Zhang, Nanhui; Luo, Ran; Cheng, Yichun; Chang, Dan; Liu, Tingting; Ge, Shu-wang; Xu, Gang
• Is Part Of: Nephrology dialysis transplantation. Volume 35(2020)Supplement 3
• Publication Date: 2020-06-06
• Subjects: Nephrology -- Periodicals; Hemodialysis -- Periodicals; Kidneys -- Transplantation -- Periodicals; Hemodialysis; Kidneys -- Transplantation; Nephrology; Periodicals; 616.61
• DOI: 10.1093/ndt/gfaa143.P0617
• Languages: English
• ISSNs: 0931-0509

Abstract

Abstract: Background and Aims: For patients with chronic kidney disease (CKD), evidence on the optimal dose of physical activity and possible harm with excessive exercise is limited. We aimed to analyze the dose-response association between leisure-time physical activity (LTPA) and mortality among participants with CKD and explore the optimal dose or possible harm associated with increased levels of physical activity. Method: Leisure-time physical activity was self-reported. Data from 4604 adults with chronic kidney disease and without missing data for LTPA and mortality in the National Health and Nutrition Examination Surveys 1999-2012 were analyzed in 2019. Mortality was from baseline until 31 December 2015 Results: During the median follow-up of 114 months, 1449 (31%) all-cause deaths were recorded. Comparing with inactive groups, the multi-variable adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of 10-59, 60-149, 150-299, and 300-599 minutes/week of leisure-time physical activity for all-cause mortality were 0.71 (0.55-0.92), 0.78 (0.62-0.98), 0.79 (0.63-0.98), and 0.75 (0.57-0.99), respectively. The benefit appeared to reach a threshold of a 41% (HR, 0.59; 95% CI, 0.41-0.84) lower risk of all-cause mortality among individuals reporting 600-1499 min/week for LTPA. And at ≥ 1500 min/week LTPA level, the HR and 95%CI were 0.66 (0.40-1.10). Conclusion: LTPA was associated with reduced all-cause mortality in participants with CKD. We observed the optimal dose at the moderate-intensity LTPA level of approximately 600-1499 min/week and no longevity benefit at ≥1500 min/week.